The patient is a 33-year-old, adopted Aboriginal man with chronic schizophrenia and multiple unsuccessful trials of antipsychotics. He had no history of diabetes. His fasting blood sugar on admission was 6.5 mmol/L. A trial of risperidone was discontinued after 6 weeks, owing to poor response. We initiated olanzapine as monotherapy, titrated to 30 mg daily. He was receiving no other regular medications. The patient was malnourished on admission, weighing 60.7 kg. This increased to 69.7 kg before the onset of DKA. Three months after starting olanzapine, he was noted to be pale and short of breath. Investigation revealed a blood sugar level 37.5 mmol/L, blood pH of 7.05, and urine ketones of 7.8. He was transferred to intensive care with DKA. It was difficult to wean the patient from intravenous insulin until olanzapine was discontinued. His insulin requirements decreased daily until glycemic control was possible with diet.
One month after the episode of DKA, the patient was becoming increasingly psychotic. Olanzapine was restarted, and 2 days later, his blood sugar measurements increased. Olanzapine was discontinued, and 24 hours later, blood sugars normalized. Blood sugar measurements became unstable, and Glyburide (sulfonylureas) 2.5 mg taken orally twice daily was added. An adequate trial of quetiapine yielded limited improvement. A trial of Clozaril (clozapine) was indicated. Two weeks after the initiation of Clozaril, blood sugar increased. Despite an increased dosage of Glyburide, blood sugar measurements continue to be unstable.
A Medline search using the term "olanzapine and diabete*" yielded 4 articles (1-4) and 4 letters (5) (6) (7) (8) . These reported 10 cases of new-onset diabetes and 8 cases of DKA after the introduction of olanzapine, including 1 death from DKA (3). Previous case reports have several confounding variables, including polypharmacy, obesity, and multiple medical problems. In our case, the patient was slim (body mass index 23), olanzapine was his only regular medication, and he was healthy.
Henderson and others reported a naturalistic study of 82 patients started on clozapine (9) . Over the 5 years of the study, 30.5% developed diabetes mellitus (DM), and 1 patient had 2 episodes of DKA. Wirshing and others summarized the case reports of 9 patients in the literature who developed DM or DKA while taking clozapineand described 4 further cases from their own practice (2) . Our case demonstrated a particular sensitivity to olanzapine and clozapine, whereas his blood sugar measurements appeared to stabilize while taking risperidone and quetiapine. There are 4 reported cases of risperidone and DM (10, 11) . There are also currently 2 reported cases of newonset DM and 1 case of DKA that developed while taking quetiapine (12, 13) .
Important factors to consider in our case are as follows: 1) the difficulty in normalizing blood sugar after the resolution of DKA, until olanzapine was discontinued; 2) the patient's decreased need for insulin until blood sugars returned to normal after 1 month; 3) the return of hyperglycemia 48 hours after the reintroduction of olanzapine; 4) the normalizing of blood sugars 24 hours after discontinuing olanzapine; and 5) the reemergence of poor glycemic control after the introduction of clozapine.
This case suggests a link between the use of atypical antipsychotics and glucose intolerance. We believe that recording baseline fasting blood sugar and regular monitoring of blood sugars should be part of routine management for patients on atypical antipsychotics.
Jeffrey C Waldman, MD Stanley Yaren, MD, FRCPC Winnipeg, Manitoba

Olecranon Bursitis as a Complication of Tardive Dyskinesia
Dear Editor:
Tardive dyskinesia (TD) is associated with numerous complications. Medical complications include disturbances of gait and posture, dysphagia, dysarthria, and loosening of natural and artificial teeth (1) . Respiratory irregularities, aspiration pneumonia (2), and rib fractures (3) have also been described. Psychosocial complications include suicide, occupational impairment, social stigmatization (1), and impaired sexual intercourse (4). This report describes an unusual case of olecranon bursitis (OB) as a complication of TD.
A 56-year-old man, treated for refractory schizophrenia since age 19 years, with paranoid delusions, auditory hallucinations, thought disorder, and episodes of aggression was managed for many years on fluphenazine decanoate. Subsequently, his daily medication for 6 years consisted of haloperidol 60 mg, chlorpromazine 1250 to 1800 mg, lithium 900 mg, procyclidine 15 mg, and diazepam 20 mg. Because he developed a bluish skin discolouration (5) , chlorpromazine was replaced by loxapine 300 mg daily. Other medications remained unchanged. He remained on this combination for 4 years. In December 1997, in addition to his psychosis, he manifested parkinsonism and akathisia. Olanzapine was prescribed and loxapine reduced. In May 2000, he showed prominent TD affecting the extremities and, to a lesser degree, the bucco-oral region. When seated, his TD arm movements resulted in his rubbing both elbows against the arms of the chair.
At the end of July, he presented to the emergency room with a swollen, red, painful left elbow and lesser involvement of the right elbow. There were abrasions over both elbows and his white cell count was elevated. A tentative diagnosis of septic OB was made. The left elbow was drained, and he was treated with oral cephalexin. The fluid showed an increase in neutrophils but no bacterial growth. His daily psychiatric medication at this time consisted of loxapine 50 mg, olanzapine 20 mg, procyclidine 15 mg, and quetiapine 50 mg . He returned 3 days later with persistent symptoms and was admitted for a 2-day course of IV cefazoline, as well as oral antibiotics. The condition improved, but in September 2000 there was persistent swelling, with draining of a yellow, odorless fluid from the left olecranon bursa. Dyskinetic movement of his arms continued, resulting in repeated trauma to the elbows when seated. Because of persistent bursitis, he underwent a bursectomy at the end of October.
Postoperatively, there was incomplete healing with persistent drainage. In December 2000, a culture of the discharge revealed a coagulase-negative staphyloccocal infection. Over the ensuing months, he received repeated courses of antibiotics for recurrent infection. The skin over the elbows was noted to be scraped. By the end of September 2001, the wound had healed. His medication at this point was clopixol depot 250 mg every 2 weeks and daily valproic acid 1500 mg, loxapine 90 mg, procyclidine 10 mg, propranolol 30 mg, and oxazepam 30 mg. The improvement in the wound was associated with a marked decrease in dyskinetic arm movements.
As far as we know, OB as a complication of TD has not been previously described. In a series of 20 patients with septic OB, Ho and others noted that 1 patient had schizophrenia together with diabetes mellitus (6) . There was, however, no recent trauma to the elbow. Laupland and others reported that 2/118 patients with septic OB had a comorbid psychiatric illness (type and details not given) (7) . Neither report mentioned the presence of TD. In our patient, direct observation of his TD movements and the presence of abrasions over his elbows point to a cause-effect relation between TD, OB, and recurrent infections. His movement disorder also resulted in delayed postoperative healing and recurrent infections that only resolved with lessened TD.
